全文获取类型
收费全文 | 12547篇 |
免费 | 800篇 |
国内免费 | 36篇 |
专业分类
耳鼻咽喉 | 93篇 |
儿科学 | 370篇 |
妇产科学 | 279篇 |
基础医学 | 1426篇 |
口腔科学 | 197篇 |
临床医学 | 1101篇 |
内科学 | 2924篇 |
皮肤病学 | 201篇 |
神经病学 | 1218篇 |
特种医学 | 460篇 |
外科学 | 1556篇 |
综合类 | 222篇 |
一般理论 | 5篇 |
预防医学 | 1440篇 |
眼科学 | 218篇 |
药学 | 908篇 |
中国医学 | 56篇 |
肿瘤学 | 709篇 |
出版年
2023年 | 71篇 |
2022年 | 72篇 |
2021年 | 250篇 |
2020年 | 138篇 |
2019年 | 249篇 |
2018年 | 414篇 |
2017年 | 296篇 |
2016年 | 257篇 |
2015年 | 295篇 |
2014年 | 366篇 |
2013年 | 538篇 |
2012年 | 792篇 |
2011年 | 909篇 |
2010年 | 520篇 |
2009年 | 420篇 |
2008年 | 800篇 |
2007年 | 892篇 |
2006年 | 820篇 |
2005年 | 838篇 |
2004年 | 807篇 |
2003年 | 801篇 |
2002年 | 736篇 |
2001年 | 293篇 |
2000年 | 362篇 |
1999年 | 261篇 |
1998年 | 105篇 |
1997年 | 63篇 |
1996年 | 53篇 |
1995年 | 55篇 |
1994年 | 63篇 |
1993年 | 45篇 |
1992年 | 98篇 |
1991年 | 80篇 |
1990年 | 63篇 |
1989年 | 69篇 |
1988年 | 46篇 |
1987年 | 41篇 |
1986年 | 44篇 |
1985年 | 35篇 |
1984年 | 20篇 |
1982年 | 22篇 |
1981年 | 27篇 |
1979年 | 26篇 |
1978年 | 28篇 |
1977年 | 24篇 |
1976年 | 26篇 |
1975年 | 14篇 |
1974年 | 16篇 |
1973年 | 13篇 |
1972年 | 19篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
12.
David Jiménez Castro Gema Díaz David Martí Carlos Escobar Javier Ortega Sergio García-Rull Joaquin Picher Antonio Sueiro 《Blood coagulation & fibrinolysis》2007,18(2):173-177
This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism. Three hundred and eighty consecutive noncancer outpatients hospitalized with an episode of symptomatic pulmonary embolism selected treatment with acenocoumarol or enoxaparin at a dose of 1 mg/kg once daily after being informed of the type of administration and expected frequency of laboratory monitoring for both medicinal products. Endpoints were symptomatic recurrent thromboembolic events evaluated by standard objective testing, and a composite endpoint of recurrent venous thromboembolism, major bleeding, and death from any cause. One hundred and ninety-nine patients (52%) chose acenocoumarol therapy and 181 chose enoxaparin monotherapy. Four patients in the enoxaparin group (2.2%) and six patients in the acenocoumarol group (3%) had an objective thromboembolic recurrence (hazard ratio, 1.35; 95% confidence interval, 0.38-4.79; P = 0.64). Nine patients in the enoxaparin group (5.0%) had a hemorrhagic complication compared with 11 in the acenocoumarol group (5.5%) (P = 0.81). The hospital length of stay was shorter with enoxaparin compared with acenocoumarol (11 versus 16 days, P = 0.0001). Enoxaparin is as effective and safe as acenocoumarol in the secondary prevention of recurrent thromboembolic disease and is associated with shorter hospitalization. 相似文献
13.
14.
15.
Heather S. Jim Michael A. Andrykowski Pamela N. Munster Paul B. Jacobsen 《Annals of behavioral medicine》2007,34(2):200-208
Background: Studies suggest that the period following completion of treatment can be distressing for cancer patients. One potentially
important predictor of distress is physical symptoms/side effects during treatment.Purpose: A longitudinal, observational design was used to examine whether the number of physical symptoms/side effects experienced
during treatment was a correlate of cancer-related distress and general distress 4 months after treatment completion, as measured
by the Impact of Events Scale and the Mental Health subscale of the Short Form-36, respectively.Methods: Participants were 151 women who had completed chemotherapy and/or radiotherapy for ductal carcinoma in situ or stage 1 or
2 breast cancer. Hierarchical multiple regression was conducted with relevant sociodemographic, clinical, and psychiatric
variables entered as controls.Results: Greater physical symptoms/side effects predicted greater total cancer-related distress, intrusive thoughts, and general distress.
Physical symptoms/side effects did not significantly predict avoidance. Follow-up analyses indicated that the relationship
between physical symptoms/side effects and general distress was mediated by both total cancer-related distress and intrusive
thoughts.Conclusions: These results suggest that patients who experience greater physical symptoms/side effects during treatment are at greater
risk for later cancer-related distress and, in turn, general distress. Future research should evaluate whether early intervention
with these patients is effective in preventing or reducing distress in the posttreatment period.
This work was supported by a grant from the National Cancer Institute (5R01 CA082822). 相似文献
16.
SK&F 86466, 6-chloro-3-methyl-2,3,4,5-tetrahydro-1-H-3-benzazepine, is a potent and selective antagonist of the α2-adrenoceptor in vitro. This compound produced a small pressor response accompanied by a marked bradycardia when administered i.v. to the pithed normotensive rat. The pressor response was not affected by reserpine treatment, pretreatment with α- or β-adrenoceptor antagonists, atropine, or hexamethonium. The bradycardia was markedly reduced by bilateral vagotomy and pretreatment with atropine and attenuated by hexamethonium. The negative chronotropic action of SK&F 86466 was abolished by a combination of vagotomy and atropine. Mediation of the bradycardia by a baroreceptor reflex was ruled out by the observations that a lack of change in heart rate was associated with the vasopressor response to phenylephrine in the pithed rat pretreated with propranolol. It is concluded that the negative chronotropic action of SK&F 86466 in the pithed rat is mediated indirectly by activation of the cholinergic innervation of the heart. 相似文献
17.
18.
19.
20.
P Férnandez-Calle J A Molina F J Jiménez-Jiménez A Vázquez M Pondal P J García-Ruiz D G Urra J Domingo R Codoceo 《Neurology》1992,42(5):1064-1066
To elucidate the possible role of vitamin E in the pathogenesis of Parkinson's disease (PD), we compared serum levels of alpha-tocopherol (vitamin E), measured by high-performance liquid chromatography, and the vitamin E/cholesterol ratio of 42 Parkinson's disease (PD) patients using their spouses as the control group. The serum levels of vitamin E did not differ significantly between the groups (13.84 +/- 0.56 micrograms/ml for PD and 14.80 +/- 0.57 micrograms/ml for controls), nor did the vitamin E/cholesterol ratio (0.64 +/- 0.03 for both groups). There was no influence of antiparkinsonian therapy on vitamin E or the vitamin E/cholesterol ratio. Serum levels of the vitamin E and vitamin E/cholesterol ratio did not correlate with age, age at onset, scores of the Unified Parkinson's Disease Rating Scale or the Hoehn and Yahr staging in the PD group. These results suggest that serum vitamin E concentrations do not play a role in the pathogenesis of PD. 相似文献